RISE - Study of the AGN1 LOEP SV Kit in Patients with Vertebral Compression Fractures

Launched by AGNOVOS HEALTHCARE, LLC · Mar 25, 2021

Keywords

ClinConnect Summary

The RISE clinical trial is studying a new treatment option called the AGN1 LOEP SV Kit for people suffering from painful vertebral compression fractures (VCFs). These fractures often occur due to osteoporosis, a condition that weakens bones. The study is looking for participants who are between 55 and 85 years old and have only one recent VCF in a specific area of their spine. To be eligible, individuals must have tried other pain management options without success and experience significant pain and disability due to their fracture.

Participants in this trial can expect to receive the AGN1 LOEP SV Kit treatment and will be followed closely by medical staff throughout the study. This is important as it helps researchers understand how safe and effective this new treatment is. The trial is currently recruiting participants across multiple centers in Europe, and it's essential for anyone considering joining to be aware of the specific criteria and commitments involved, including attending follow-up appointments to track progress.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject is a male or female 50 years of age or older at time of study treatment.
• • 2. Criterion omitted
• • 3. Subject has only one (1) acute VCF. Subjects are eligible if they have an asymptomatic healed VCF at any non-target vertebral level.
• 4. This VCF meets all of the following criteria:
• • 1. Fracture due to diagnosed or presumed underlying osteoporosis
• • 2. VCF from T1 to L5 inclusive
• • 3. Fracture age ≤6 months at time of treatment
• • 5. Target VCF shows loss of height in the anterior or middle portion of the vertebral body of not more than 50% based on X-ray at baseline.
• • 6. Target VCF is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI, bone scan, CT, serial radiographs, or other imaging demonstrating acuity.
• • 7. Subject has central pain upon palpation over the spinal process at the target vertebral body.
• • 8. Subject has failed conservative medical therapy, defined as either having a VAS back pain score of ≥ 70 mm after 24 hours to 6 weeks of conservative care or a VAS back pain score of ≥ 50 mm after 6 weeks of conservative care.
• • 9. Subject has an Oswestry Disability Index (ODI) score of ≥ 30%.
• • 10. Subject is capable of giving written informed consent to participate in the study.
• • 11. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full length of the study has been documented.
• Exclusion Criteria:
• • 1. Target VCF is due to underlying or suspected tumor.
• • 2. Target VCF is due to high-energy trauma.
• • 3. Target VCF is diagnosed as an osteonecrotic fracture.
• • 4. Target VCF has segmental kyphosis of \> 30°.
• • 5. Target VCF is unstable including split or burst fractures.
• • 6. Subject has had any prior surgical treatment at the target VCF or adjacent vertebral level (above or below VCF).
• • 7. Subject has neurologic symptoms, deficits, or radiculopathy related to the VCF.
• • 8. Subject has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated.
• • 9. Subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis).
• • 10. Subject has spondylolisthesis \> Grade 1 at target vertebral body.
• • 11. Subject has pain due to any other condition that requires daily narcotic medication.
• • 12. Subject has severe cardiopulmonary deficiencies.
• • 13. Subject has a bleeding disorder.
• • 14. Subject has a Body Mass Index (BMI) \> 35.
• • 15. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
• • 16. Subject has a history of tuberculosis spondylitis.
• • 17. Subject has a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for five (5) years.
• • 18. Subject is on oral or parenteral immune-suppressive drugs.
• • 19. Subject has an active bone infection at target VCF.
• • 20. Subject has uncontrolled diabetes mellitus, as determined by the judgment of the Investigator.
• • 21. Subject has severe renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \< 30 mL/min.
• • 22. Subject has a diagnosed calcium metabolism disorder.
• • 23. Subject has known allergies to calcium-based bone void fillers.
• • 24. Subject is pregnant or planning to become pregnant during participation in the study.
• • 25. In the judgment of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues).
• • 26. Subject is currently enrolled in another interventional clinical study.